enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24

Stock Information for Volato Group Inc. Class A

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Volato Group Inc. Class A

enVVeno Medical Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference
JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting
enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer
Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery
VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium
enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment
The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.